乙型肝炎病毒基因型与拉米夫定治疗效应关系研究

中国临床药理学与治疗学 ›› 2004, Vol. 9 ›› Issue (9): 1050-1053.

乙型肝炎病毒基因型与拉米夫定治疗效应关系研究

张红河, 邵听军, 杨仲国

杭州市第一人民医院基因诊断实验室, 杭州310006, 浙江

收稿日期:2004-06-29 修回日期:2004-08-05 出版日期:2004-09-26 发布日期:2020-11-23
通讯作者: 张红河, 男, 技师, 主要研究方向:基因诊断技术。Tel:0571-87065701-30808 E-mail:zhh @dna.net.cn

Research on relation between genotype and effect of lamivudine in patient with hepatitis B virus infection

ZHANG Hong-He, SHAO Ting-Jun, YANG Zhong-Guo

Department of GeneDiagnosis Laboratory, The First Hospital of Hangzhou, Hangzhou 310006, Zhejiang, China

Received:2004-06-29 Revised:2004-08-05 Online:2004-09-26 Published:2020-11-23

摘要/Abstract

摘要： 目的: 探讨乙型肝炎病毒基因型与拉米夫定治疗效应的关系。方法: 采用DNA 测序和寡核苷酸芯片技术, 检测分析了41 例使用拉米夫定治疗的乙型肝炎患者的基因型与酪氨酸-蛋氨酸-天冬氨酸-天冬氨酸(YMDD) 变异情况, 同时跟踪观察了患者治疗前、治疗后3 、6 、9 、12 个月的乙型肝炎病毒(HBV) DNA 和丙氨酸转氨酶(ALT) 水平。结果: 41 例HBV 患者中B 基因型21 例(51. 2 %), C 基因型20 例(48. 8 %); 拉米夫定治疗前与治疗12 个月后B 基因型与C 基因型两组间ALT 水平差异无显著性(P > 0. 05) 。拉米夫定治疗乙型肝炎过程中C 基因型HBV DNA 转阴率显著高于B 基因型, B 基因型HBV DNA 反跳率显著高于C 基因型(P<0. 01) 。C 基因型YMDD 突变率与B 基因型差异无显著性(P >0. 05) 。结论: HBV 基因型与拉米夫定治疗效应存在一定的相关性, C 基因型对拉米夫定的治疗效应较好。

关键词: 肝炎病毒, 乙型, 基因型, 拉米夫定, 治疗效应

Abstract: AIM: To investigate the relation between the genotype and the effect of lamivudine in patient with hepatitis B virus infection.METHODS: The genotype of hepatitis B virus and the YMDD mutation of 41 chronic hepatitis B patients with lamivudine treatment were detected and analyzed by DNA sequencing and oligochip technology. The DNA of HBV and the levels of ALT were detected before therapy and after 3, 6, 9, and 12 months with lamivudine treatment.RESULTS: 21 samples were classified as genotype B (51. 2 %) and 20 as genotype C (48. 8 %) in 41 samples. There were no significant differences on the levels of ALT between genotype B and C before and after lamivudine treatment for 12months (P > 0. 05). After lamivudine treatment, the rate of the transform negative of HBV DNA in genotype C was significantly higher than that in genotype B, and the rate of the bounce of HBV DNA in genotype B was higher than that in genotype C (P<0. 01). There were no significant difference on the rate of mutation in YMDD betmeen genotype B and C (P >0. 05).CONCLUSION: There may be a relation between the effect of lamivudine and the genotype of Hepatitis B virus.The effect of the lamivudine treatment may be better in the patients with genotype C.

Key words: hepatitis B virus, genotype, lamivudine, efficacy, genotype

中图分类号:

R978.7

张红河, 邵听军, 杨仲国. 乙型肝炎病毒基因型与拉米夫定治疗效应关系研究[J]. 中国临床药理学与治疗学, 2004, 9(9): 1050-1053.

ZHANG Hong-He, SHAO Ting-Jun, YANG Zhong-Guo. Research on relation between genotype and effect of lamivudine in patient with hepatitis B virus infection[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(9): 1050-1053.

参考文献

1 Okamoto H, Tsuda F, Sakugawa H.Typing hepatitis B virus by homology in nucleotide sequence: comparison of surfase subtype [J]. J Gen Virol, 1988;69(10): 2575-83
2 Norder H, Courouce AM, Magnius LO.Complete genomes phylogenetic relatedness and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes [J]. Virology, 1994; 198(2): 489-503
3 Stuyver L, De GS, Van GC, Zoulim F, Fried M, Schinazi RF. A new genotype of hepatitis B virus:complete genome and phylogenetic relatedness[J]. J Gen Virol, 2000;81(1): 167-74
4 Arauz RP, Norder H, Robertson BH, Magnius LO.Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America[J]. J Gen Virol, 2002; 83(8): 2059-73
5 Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients[J]. Gastroenterology, 2002; 123(6): 1848-56
6 Wai CT, Chu CJ, HussainM, Lok AS. HBV genotype B is associated with better response to interferon therapy in HbeAg(+) chronic hepatitis than genotype C[J]. Hepatology, 2002; 36 (6): 1425-30
7 Chayama K, Suzuki Y, Kobayashi M. Emergence and takeover of YMDD motif mutant Hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy[J]. Hepatology, 1998; 27(6): 1711-6
8 Lau DT, Khokhar MF, Doo E.Long-term therapy of chronic Hepatitis B with lamivudine[J]. Hepatology, 2000;32(4): 828-34
9 Bartholomew MM, Jansen RW, Jeffers LJ. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation[J]. Lancet, 1997;349(1): 20-2
10 Honkoop P, Niesters HG, deMan RA, Osterhaus AD, Schalm SW.Lamivudine resistance in immunocompetent chronic hepatitis B incidence and patterns[J]. J Hepatol, 1997;26(6): 1393-5
11 LindhM, Andersson AS, Gusdal A.Genotypes, NT 1858 variants, and geographic origin of hepatitis B virus--large-scale analysis using a new genotyping method[J]. J Infect Dis, 1997;175(6): 1285-93
12 Norder H, Hammas B, Lee SD.Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen[J]. J Gen Virol, 1993;74(7): 1341-8
13 Norder H, Hammas B, Lofdahl S, Courouce AM, Magnius LO.Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains[J]. J Gen Virol, 1992;73(5): 1201-8
14 Allen MI, Deslauriers M, Andrews CW.Identification and characterization of mutations in hepatitis B virus resistant to lamivudine[J]. Hepatology, 1998;27(6): 1670-7
15 Norder H, Courouce AM, Magnius LO.Molecular basis of hepatitis B virus serotype variations within the four major subtypes[J]. J Gen Virol, 1992;73(12): 3141-5

[1]	戚林玲, 刘寿荣. 丙酚替诺福韦在乙肝母婴阻断中的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(5): 578-582.
[2]	陶承静, 刘寿荣, 程晓仙, 胡健女, 白秀丽, 张素英, 赵春, 左中宝. 替诺福韦不同产后停药时间对乙型肝炎病毒标志物、病毒学以及生化学指标的影响[J]. 中国临床药理学与治疗学, 2021, 26(10): 1146-1152.
[3]	万萍，刘亮，张萍，张忠东. 奥氮平在精神分裂症中的血清药物浓度/剂量比影响因素研究[J]. 中国临床药理学与治疗学, 2019, 24(9): 1024-1029.
[4]	曾传莉，胡爱荣，胡耀仁，袁刚，朱德东，石小军. 恩替卡韦联合微生态制剂治疗乙肝肝硬化患者的临床疗效研究[J]. 中国临床药理学与治疗学, 2018, 23(7): 796-801.
[5]	袁刚，胡爱荣，胡耀仁，曾传莉，朱德东，石小军. 恩替卡韦和阿德福韦酯治疗代偿期乙肝肝硬化临床疗效及远期预后[J]. 中国临床药理学与治疗学, 2018, 23(2): 170-174.
[6]	霍娜，陆海英，王贵强，黄明杰，吴赤红，蔺小红. 长期应用核苷（酸）类药物治疗对慢乙肝患者肾功能的影响[J]. 中国临床药理学与治疗学, 2017, 22(9): 1029-1034.
[7]	邢欣，李丽萍，王鹿，肖莉，孙丽新. 丙型病毒性肝炎中肝脏巨噬细胞的变化及作用[J]. 中国临床药理学与治疗学, 2017, 22(9): 1072-1076.
[8]	陈勇华，曹群奋，洪琼怿，王树民. 替诺福韦酯治疗对慢性乙型肝炎患者血清FGF-23、β2-MG、Cys-C及RBP水平的影响[J]. 中国临床药理学与治疗学, 2017, 22(7): 799-804.
[9]	李梦莹，徐凤艳，黄继汉，李禄金，杨娟，许羚，何迎春，郑青山，王鲲. 病毒动力学模型及评价[J]. 中国临床药理学与治疗学, 2016, 21(6): 653-660.
[10]	张银妆，莫珍珍，戴玮，石珂，陈碧莲. 氯吡格雷对基于分型的健康人血浆eNOS和NO水平影响的研究[J]. 中国临床药理学与治疗学, 2016, 21(3): 298-305.
[11]	沈斌，蒋利亚，张小平，邓敏. 药物利用评价法和药物利用评估法在慢性乙型肝炎药物治疗中的应用研究[J]. 中国临床药理学与治疗学, 2016, 21(12): 1419-1424.
[12]	张毅，余永胜，汤正好，陈小华，王鹏，江红，奚敏，臧国庆. 恩替卡韦联合苦参素改善HBeAg阳性慢性乙型肝炎患者Th1/Th2失平衡临床研究[J]. 中国临床药理学与治疗学, 2016, 21(10): 1168-1172.
[13]	刘敏, 肖飞燕, 王晓飞, 张伟, 周淦. 基因多态性、药物联用和临床因素对氯吡格雷疗效的影响及相关的基因型分布[J]. 中国临床药理学与治疗学, 2015, 20(8): 915-922.
[14]	李小宁, 杨正海, 李静. 不同基因型丙型肝炎病毒非结构蛋白NS3对端粒酶活性的研究[J]. 中国临床药理学与治疗学, 2015, 20(2): 128-131.
[15]	王玉萍, 李小宁, 张莺莺. 洋葱伯克霍尔德复合体研究新进展[J]. 中国临床药理学与治疗学, 2014, 19(1): 101-104.